Investigational drug · Phase 2
IDP-121
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer ( SCLC ), Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "IDP-121"
First trial start
2023
Jun 5, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IDP-121", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer ( SCLC )
- Multiple Myeloma (MM)
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Double Hit Lymphoma
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Chronic Lymphocytic Leukemia (CLL)
- Triple Hit Lymphoma
Approved drugs for the same conditions: Small cell lung cancer · Multiple myeloma · Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "IDP-121" as an intervention, largest first.
- Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne VulgarisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02932306 · 820 participants · Start Nov 3, 2015 · Primary completion Feb 22, 2017
Drug: IDP-121 Lotion; IDP-121 Vehicle Lotion · For: Acne
Sites: Guntersville, Alabama; Phoenix, Arizona; Hot Springs, Arkansas · 39 sites in all
- Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02965456 · 820 participants · Start Nov 4, 2015 · Primary completion Feb 23, 2017
Drug: IDP 121 Lotion; IDP-121 Vehicle Lotion · For: Acne
Sites: Glendale, Arizona; Rogers, Arkansas; Anaheim, California · 34 sites in all
- A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisPivotal-lookingStatus unknown
Valeant PharmaceuticalsIndustry
NCT02491060 · 800 participants (planned) · Start Sep 2015 · Primary completion Jul 2016
Drug: IDP-121 Lotion; IDP-121 Vehicle Lotion · For: Acne Vulgaris
- A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisPivotal-lookingStatus unknown
Valeant PharmaceuticalsIndustry
NCT02535871 · 800 participants (planned) · Start Sep 2015 · Primary completion Jul 2016
Drug: IDP-121 Lotion; IDP-121 Vehicle Lotion · For: Acne Vulgaris
IDP Discovery Pharma S.L.Industry
NCT07864207 · 60 participants (planned) · Start Jul 28, 2026 · Primary completion Jul 30, 2028
Drug: IDP-121 · For: Small Cell Lung Cancer ( SCLC )
Sites: Barcelona, Spain; Las Palmas de Gran Canaria, Spain; Madrid, Spain · 10 sites in all
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruiting
IDP Discovery Pharma S.L.Industry
NCT05908409 · 37 participants (planned) · Start Jun 5, 2023 · Primary completion Dec 22, 2025
Drug: IDP-121 · For: Multiple Myeloma (MM); Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double Hit Lymphoma and 3 more
Sites: Santander, Spain; Salamanca, Spain; Barcelona, Spain · 11 sites in all
- Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne VulgarisCompleted
Bausch Health Americas, Inc.Industry
NCT02849860 · 20 participants · Start Feb 2014 · Primary completion Sep 2016
Drug: IDP-121 Lotion · For: Acne
Sites: Austin, Texas; College Station, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Small Cell Lung Cancer ( SCLC )
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.